

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 13G**  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)

(Amendment No. )<sup>1</sup>

---

Blueprint Medicines Corporation  
(Name of Issuer)

---

Common Stock, \$0.001 par value  
(Title of Class of Securities)

---

09627Y109  
(CUSIP Number)

---

April 30, 2015  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

---

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

---

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>Biotechnology Value Fund, L.P.                                |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Delaware  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares       |
|  | 6   | SHARED VOTING POWER<br><br>870,111      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares  |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>870,111 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>870,111                   |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>3.4%                                 |   |
| 12   | TYPE OF REPORTING PERSON<br><br>PN  |   |

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>Biotechnology Value Fund II, L.P.                             |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Delaware  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares       |
|  | 6   | SHARED VOTING POWER<br><br>486,809      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares  |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>486,809 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>486,809                   |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>1.9%                                 |   |
| 12   | TYPE OF REPORTING PERSON<br><br>PN  |   |

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>Investment 10, L.L.C.   |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Illinois  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares       |
|  | 6   | SHARED VOTING POWER<br><br>215,872      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares  |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>215,872 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>215,872                   |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>Less than 1%                         |   |
| 12   | TYPE OF REPORTING PERSON<br><br>OO  |   |

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>MSI BVF SPV, LLC  |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Delaware  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares       |
|  | 6   | SHARED VOTING POWER<br><br>122,616      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares  |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>122,616 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>122,616                   |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>Less than 1%                         |   |
| 12   | TYPE OF REPORTING PERSON<br><br>OO  |   |

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>BVF Partners L.P.   |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Delaware  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares         |
|  | 6   | SHARED VOTING POWER<br><br>1,695,408      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares    |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>1,695,408 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>1,695,408                 |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>6.6%                                 |   |
| 12   | TYPE OF REPORTING PERSON<br><br>PN, IA  |   |

|  |   |   |
|--|---|---|
| 1  | NAME OF REPORTING PERSON<br><br>BVF Inc.  |   |
| 2  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x<br>(b) o                               |   |
| 3  | SEC USE ONLY  |   |
| 4  | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>Delaware  |   |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares         |
|  | 6   | SHARED VOTING POWER<br><br>1,695,408      |
|  | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares    |
|  | 8   | SHARED DISPOSITIVE POWER<br><br>1,695,408 |
| 9  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>1,695,408                 |   |
| 10   | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> |   |
| 11   | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>6.6%                                 |   |
| 12   | TYPE OF REPORTING PERSON<br><br>CO  |   |

|   |   |   |
|---|---|---|
| 1   | NAME OF REPORTING PERSON<br><br>Mark N. Lampert   |   |
| 2   | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input checked="" type="checkbox"/> (b) <input type="checkbox"/> |   |
| 3   | SEC USE ONLY  |   |
| 4   | CITIZENSHIP OR PLACE OF ORGANIZATION<br><br>United States   |   |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5   | SOLE VOTING POWER<br><br>0 shares         |
|   | 6   | SHARED VOTING POWER<br><br>1,695,408      |
|   | 7   | SOLE DISPOSITIVE POWER<br><br>0 shares    |
|   | 8   | SHARED DISPOSITIVE POWER<br><br>1,695,408 |
| 9   | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br><br>1,695,408   |   |
| 10  | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>                         |   |
| 11  | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br><br>6.6%   |   |
| 12  | TYPE OF REPORTING PERSON<br><br>IN  |   |

Item 1(a). Name of Issuer:  
Blueprint Medicines Corporation, a Delaware corporation (the “Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices:  
215 First Street  
Cambridge, Massachusetts 02142

Item 2(a). Name of Person Filing  
Item 2(b). Address of Principal Business Office or, if None, Residence  
Item 2(c). Citizenship

Biotechnology Value Fund, L.P. (“BVF”)  
1 Sansome Street, 30<sup>th</sup> Floor  
San Francisco, California 94104  
Citizenship: Delaware

Biotechnology Value Fund II, L.P. (“BVF2”)  
1 Sansome Street, 30<sup>th</sup> Floor  
San Francisco, California 94104  
Citizenship: Delaware

Investment 10, L.L.C. (“ILL10”)  
900 North Michigan Avenue, Suite 1100  
Chicago, Illinois 60611  
Citizenship: Illinois

MSI BVF SPV, LLC (“MSI”)  
c/o Magnitude Capital, LLC  
601 Lexington Avenue, 59th Floor  
New York, NY 10022  
Citizenship: Delaware

BVF Partners L.P. (“Partners”)  
1 Sansome Street, 30<sup>th</sup> Floor  
San Francisco, California 94104  
Citizenship: Delaware

BVF Inc.  
1 Sansome Street, 30<sup>th</sup> Floor  
San Francisco, California 94104  
Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)  
1 Sansome Street, 30<sup>th</sup> Floor  
San Francisco, California 94104  
Citizenship: United States

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

Item 2(d). Title of Class of Securities:

Common stock, \$0.001 par value (the "Common Stock")

Item 2(e). CUSIP Number:

09627Y109

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

/x/ Not applicable.

(a)  // Broker or dealer registered under Section 15 of the Exchange Act.

(b)  // Bank as defined in Section 3(a)(6) of the Exchange Act.

(c)  // Insurance company as defined in Section 3(a)(19) of the Exchange Act.

(d)  // Investment company registered under Section 8 of the Investment Company Act.

(e)  // An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

(f)  // An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

(g)  // A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

(h)  // A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

(i)  // A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

(j)  // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

(k)  // Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on May 8, 2015 (i) BVF beneficially owned 870,111 shares of Common Stock, (ii) BVF2 beneficially owned 486,809 shares of Common Stock, (iii) ILL10 beneficially owned 215,872 shares of Common Stock, and (iv) MSI beneficially owned 122,616 shares of Common Stock.

Partners, as the general partner of BVF and BVF2 and the investment adviser of ILL10 and MSI may be deemed to beneficially own 1,695,408 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, ILL10 and MSI.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,695,408 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,695,408 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, ILL10 and MSI and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 25,831,965 shares of Common Stock outstanding, as disclosed in the Issuer's Prospectus filed on Form 424B4 with the Securities and Exchange Commission on April 30, 2015.

As of the close of business on May 8, 2015, (i) BVF beneficially owned approximately 3.4% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 1.9% of the outstanding shares of Common Stock, (iii) ILL10 beneficially owned less than 1% of the outstanding shares of Common Stock, (iv) MSI beneficially owned less than 1% of the outstanding shares of Common Stock and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 6.6% of the outstanding shares of Common Stock.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: May 8, 2015

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its investment adviser  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

MSI BVF SPV, LLC

By: BVF Partners L.P., its investment adviser  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BVF INC.

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

/s/ Mark N. Lampert  
MARK N. LAMPERT



Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated May 8, 2015 with respect to the shares of Common Stock of Blueprint Medicines Corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: May 8, 2015

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its investment adviser  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

MSI BVF SPV, LLC

By: BVF Partners L.P., its investment adviser  
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

BVF INC.

By: /s/ Mark N. Lampert  
Mark N. Lampert  
President

/s/ Mark N. Lampert  
MARK N. LAMPERT